Resultats globals: 1 registres trobats en 0.01 segons.
Articles, 1 registres trobats
Articles 1 registres trobats  
1.
12 p, 1.1 MB Masitinib as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis : a randomized clinical trial / Mora, J. S. (ALS Unit. Hospital San Rafael) ; Genge, A. (Department of Neurology and Neurosurgery. Montreal Neurological Institute and Hospital. McGill University) ; Chiò, Adriano (Department of Neuroscience. University of Turin) ; Estol, C. J. (Neurological Center for Treatment and Rehabilitation) ; Chaverri, D. (Hospital Carlos III (Madrid)) ; Hernández, M. (Hospital Carlos III (Madrid)) ; Marín, S. (Hospital Carlos III (Madrid)) ; Mascias, J. (Hospital Carlos III (Madrid)) ; Rodriguez, G. E. (Neurology Department. Neuron Motor Disease Clinic. Hospital JM Ramos) ; Povedano, M. (Institut d'Investigació Biomèdica de Bellvitge) ; Paipa, A. (Institut d'Investigació Biomèdica de Bellvitge) ; Dominguez, Raúl (Institut d'Investigació Biomèdica de Bellvitge) ; Gamez, Josep (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Salvado, M. (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Lunetta, C. (NEMO Clinical Centre. Serena Onlus Foundation) ; Ballario, C. (Neurorosario) ; Riva, N. (Department of Neurology-INSPE. San Raffaele Scientific Institute) ; Mandrioli, J. (Department of Neurosciences. St. Agostino-Estense Hospital. Azienda Ospedaliero Universitaria di Modena) ; Moussy, A. (AB Science) ; Kinet, J. P. (Department of Pathology. Harvard Medical School and Beth Israel Deaconess Medical Center) ; Auclair, C. (Department of Biology. Université Paris Sud Université Paris-Saclay CNRS UMR 8113. Ecole Normale Supérieure de Cachan) ; Dubreuil, P. (Institut Paoli-Calmettes Cancer Centre (Marsella, França)) ; Arnold, V. (AB Science) ; Mansfield, C. D. (AB Science) ; Hermine, O. (Imagine Institute. INSERM UMR 1163 and CNRS ERL 8254. Laboratory of Cellular and Molecular Mechanisms of Hemathological Disorders and Therapeutic Implication. Hôpital Necker) ; Universitat Autònoma de Barcelona
Objective: To assess masitinib in the treatment of ALS. Methods: Double-blind study, randomly assigning 394 patients (1:1:1) to receive riluzole (100 mg/d) plus placebo or masitinib at 4. 5 or 3. 0 mg/kg/d. [...]
2020 - 10.1080/21678421.2019.1632346
Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, Vol. 21 Núm. 1-2 (february 2020) , p. 5-14  

Us interessa rebre alertes sobre nous resultats d'aquesta cerca?
Definiu una alerta personal via correu electrònic o subscribiu-vos al canal RSS.